Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO) -- Ignore unavailable to you. Want to Upgrade?

To: Sr K who wrote (86)	1/7/2000 5:10:00 PM
From: Edscharp	Respond to of 286

Quadruple? Read this. From the Medical Technology Stock Letter - Dec 29, 1999 "Hyseq enters the new year gaining momentum. There will continue to be announcements about new genes discovered, additional partnerships and progress with their lead products. Most important will be the cumulative impact of this progress in making investors aware HYSQ is a leader in the genomics sector and is establishing a very strong patent position. This is despite the fact that they currently have a market capitalization of only $235 million! This compares with $2.48 billion for Human Genome Sciences, their most similar competitor. We think this should result in another good year for HYSQ. HYSQ is a buy under $12." The stock was already $18/share when this was written.